Aquestive Therapeutics Inc — Quarterly Cash Flow (NASDAQ:AQST) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 101.42 M102.23 M93.7 M163.56 M160.43 M Total liabilities 161.58 M163.16 M166.29 M167.67 M194.09 M Total equity -60.16 M-60.93 M-72.59 M-4.11 M-33.66 M Total liabilities & shareholders' equities 101.42 M102.23 M93.7 M163.56 M160.43 M Total debt 50.48 M50.36 M50.24 M50.11 M49.97 M Net debt 50.48 M-18.3 M-10.3 M-78.95 M49.97 M

News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation (NASDAQ:AQST)

Aquestive Therapeutics chief people officer Boyd sells $124k in stock

Aquestive Therapeutics CEO Barber sells $753,965 in stock

Aquestive Therapeutics SVP Cioffi sells $105k in shares

Aquestive therapeutics chief legal officer Braender sells $167k in stock

Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval

Aquestive at Leerink Conference: Strategic Focus on Anaphylm

Citizens reiterates Aquestive stock rating on clear FDA path

Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript

Aquestive Q4 2025 slides detail FDA setback, resubmission plan

Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics